Paper Details

  1. Home
  2. Paper Details

Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses.

Author: StockflethEggert, WillersChristoph, ZwingersThomas

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Topical 0.5% 5-FU/SA demonstrated superior sustained clinical efficacy versus diclofenac/HA with acceptable tolerability. Patient satisfaction was high.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Actinic keratoses (AK) have been classified as early in situ squamous cell carcinomas and should be treated. OBJECTIVES: To evaluate the clinical benefit of 5-fluorouracil 0.5%/salicylic acid 10.0% (5-FU/SA) versus 3% diclofenac/hyaluronic acid (HA) for the treatment of AK and report pa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1684/ejd.2012.1707

データ提供：米国国立医学図書館（NLM）

Treating Actinic Keratoses: A Comparative Study

This research explores the effectiveness of different topical treatments for [actinic keratoses (AKs)], precancerous skin lesions that can progress to squamous cell carcinoma. The authors conducted a randomized, double-blind, controlled trial to compare the efficacy of 5-fluorouracil/salicylic acid (5-FU/SA) versus diclofenac/hyaluronic acid (HA) in treating AKs.

5-FU/SA Demonstrates Superior Sustained Efficacy

The study revealed that topical 5-FU/SA demonstrated superior sustained clinical efficacy in treating AKs compared to diclofenac/HA. At 12 months after the end of treatment, a significantly higher percentage of lesions did not recur in the 5-FU/SA group compared to the vehicle and diclofenac/HA groups. This finding suggests that 5-FU/SA might be a more effective treatment option for AKs, offering greater long-term control over lesion recurrence.

Patient Satisfaction and Tolerability

The study also evaluated patient satisfaction and tolerability of the treatments. Patients in the 5-FU/SA group reported higher satisfaction with the treatment, although they experienced more local side effects, such as inflammation and burning. Overall, patients found the treatments to be acceptable and did not experience significant difficulties with application or handling.

Dr.Camel's Conclusion

This study provides valuable insights into the comparative efficacy of different topical treatments for AKs. The researchers' findings suggest that 5-FU/SA might be a more effective treatment option for AKs, offering greater long-term control over lesion recurrence. However, it's important to consider the potential for local side effects and to weigh the benefits and risks carefully when selecting a treatment for AKs.

Date :
  1. Date Completed 2012-09-04
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

22494856

DOI: Digital Object Identifier

10.1684/ejd.2012.1707

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.